For Biopharma

For Biopharma NeXT Personal | MRD Liquid Biopsy ImmunoID NeXT | Tissue Biomarker Platform

male doctor with protective glasses handling lab equipment

ImmunoID NeXT®Multidimensional Tumor Sequencing and Analysis

Optimize your research and clinical trials with an all-in-one platform that redefines immunogenomics.

ImmunoID NeXT® is a comprehensive tumor tissue profiling platform that enables you to interrogate the complex interactions between the tumor and its microenvironment, including critical tumor- and immune-related information such as T-cell and B-cell receptor (TCR/BCR) repertoire, established biomarkers (ex: TMB), and more.

Your next-generation biomarker discovery platform

>90% success rate⁴

In processing challenging samples like formalin-fixed & paraffin-embedded (FFPE) slide

Sample-sparing

Approach enabling dual DNA and RNA extraction from the same tumor specimen, using as few as five FFPE slides

>1,000X coverage

Across 247 cancer-related genes plus 300X mean exome coverage (>20,000 genes)

Download Flyer

One sample. One platform. Multidimensional insights.

We know that patient samples are precious. ImmunoID NeXT® maximizes the data generated from a single sample. Our platform consolidates multiple modules to deliver insights into a broad range of biomarkers from a small amount of input material (as few as 5 FFPE slides).

Using our advanced analytical algorithms, you can interrogate critical tumorand immune-related information, including:

Tumor mutational burden (TMB), microsatellite instability (MSI), immune cell enrichment, and more
Advanced neoantigen prediction, algorithms detecting human leukocyte antigens loss of heterozygosity (HLA LOH)^5,6
Impact on tumor microenvironment, including alterations in the intratumoral immunocellular profile, expansion of expressed T cell receptor (TCR) clonotypes,and much more
Advanced biomarker readouts like neoantigen presentation score (NEOPS) that have been shown to be predictive of immunotherapy response in melanoma³

Download Brochure

Innovations powered by ImmunoID NeXT®

Enabling therapeutic mRNA cancer vaccines¹

ImmunoID NeXT® platform was used to assess each patient s mutanome, the entirety of the somatic cancer mutations.¹
This data informed the production of the mRNA-4157 individualized neoantigen therapy.¹
Adjuvant mRNA-4157 plus pembrolizumab prolonged recurrence-free survival versus pembrolizumab monotherapy in patients with resected high-risk melanoma and showed a manageable safety profile.¹

Read Publication

Delivering biomarkers for cell therapy response²

The case study patient had advanced gastric adenocarcinoma and previously had cancer progression on standard chemotherapy and anti-PD-1 therapy.²
Post-treatment biomarker assays show that the anti-tumor immune response induced by agenT-797 resulted in durable tumor response.²
Sequencing data was analyzed using Personalis’ ImmunoID NeXT® analytics platform and identified key biomarkers that correlated with the clinical outcome.²

Read Publication

Research that empowers
effective biomarker discovery

Leveraging exome-and-transcriptome-scale sequencing, our specialized analytics give you visibility into established and investigational biomarkers to help you determine which patient will have the best response to the drug.

Better understand therapy response

Using ImmunoID NeXT® has allowed our partners to discover biomarkers that correlate with improved therapy response.^1,2

Personalized therapies and vaccines

Our platform has helped researchers identify more effective neoantigens to develop personalized vaccines.¹

Learn More

About how we accelerate cancer biomarker discovery and deployment.^1,2

Request Info

How it works

Enhanced performance

Augmented for oncology

Advanced bioinformatics

Ultra-high sensitivity

Enhanced performance

Enhanced performance for challenging samples

Leverage protocols that allow reliable dual extraction of DNA and RNA from the same tumor specimen to:

Deliver >90% success rate with difficult samples
Ensure samples are used sparingly (use as few as 5 FFPE slides or 1mm³ tissue volume)

Request Info

Augmented for oncology

Augmented coverage

Discover more with our proprietary ACE® Technology which covers the entire ~20,000-gene footprint of both the exome and transcriptome, including difficult-to-sequence regions:

300X coverage for tumor samples and 150X coverage for normal samples
200M total reads (WTS)
Clinical-grade coverage (>1,000X) across 247 cancer related genes
Ultra-deep coverage of TCR/BCR gene regions, MSI, oncoviruses, and HLA

Request Info

Advanced bioinformatics

Receive data provided by advanced bioinformatics pipelines that:

Integrate both proprietary and advanced, publicly available in silico tools
Generate actionable insights from comprehensive DNA and RNA data

Request Info

Ultra-high sensitivity

Ultra-high sensitivity and specificity

Confidently conduct clinical trials with a platform that enables accurate detection of SNVs, indels, gene fusions, and CNAs. Download our Analytical Validation White Paper.

Request Info

Accelerating cancer biomarker
discovery and deployment^1,2

Designed to support the entire spectrum of precision oncology, Personalis is paving the way for the development and commercialization of new cancer therapies. From improved processes to advanced biomarker assays and analytics, the technology we pioneer is helping our biopharma partners harness the power of genomic data, making personalized cancer treatment a reality for all patients.

Resources

ImmunoID NeXT®

Product Overview

Download PDF

ImmunoID NeXT®

Product Brochure

Dowload PDF

Biomarker Discovery Solutions

Learn More

Prevailing Cancer Immunotherapy Challenges

Learn More

See all ImmunoID Resources

Learn More

References

Weber JS, Carlino MS, Khattak A, et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet Lond Engl. 2024;403(10427):632-644. doi:10.1016/S0140-6736(23)02268 7
Hadfield MJ, Safran H, Purbhoo MA, Grossman JE, Buell JS,Carneiro BA. Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT). Oncogene. Published online January 29, 2024:1 5. doi:10.1038/s41388-024-02948-y
Charles W. Abbott, et al. Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms. Clinical Cancer Research. Published 1 August 2021; 27 (15): 4265–4276. https://doi.org/10.1158/1078-0432.CCR-20-4314
Internal data on file.
Rachel Marty Pyke, Dattatreya Mellacheruvu, Dea, S., Abbott, C. W., McDaniel, L., Bhave, D. P., Zhang, S. V., Lévy, E., Bartha, G., West, J., Snyder, M., Chen, R., & Sean Michael Boyle. (2022). A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-29203-w
Pyke, R. M., Mellacheruvu, D., Dea, S., Abbott, C., Zhang, S. V., Phillips, N. A., Harris, J., Bartha, G., Desai, S., McClory, R., West, J., Snyder, M. P., Chen, R., & Boyle, S. M. (2023). Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation. Molecular & Cellular Proteomics: MCP, 22(4), 100506. https://doi.org/10.1016/j.mcpro.2023.100506

PRO-1074-v1

We can see
what others miss.

Request Info

SEARCH

ImmunoID NeXT®Multidimensional Tumor Sequencing and Analysis

Optimize your research and clinical trials with an all-in-one platform that redefines immunogenomics.

Your next-generation biomarker discovery platform

>90% success rate4

Sample-sparing

>1,000X coverage

One sample. One platform. Multidimensional insights.

Innovations powered by ImmunoID NeXT®

Enabling therapeutic mRNA cancer vaccines1

Delivering biomarkers for cell therapy response2

Research that empowers effective biomarker discovery

Better understand therapy response

Personalized therapies and vaccines

Learn More

How it works

Enhanced performance

Augmented for oncology

Advanced bioinformatics

Ultra-high sensitivity

Enhanced performance

Enhanced performance for challenging samples

Augmented for oncology

Augmented coverage

Advanced bioinformatics

Advanced bioinformatics

Ultra-high sensitivity

Ultra-high sensitivity and specificity

Accelerating cancer biomarker discovery and deployment1,2

Resources

ImmunoID NeXT®

ImmunoID NeXT®

Biomarker Discovery Solutions

Prevailing Cancer Immunotherapy Challenges

See all ImmunoID Resources

References

We can see what others miss.

>90% success rate⁴

Enabling therapeutic mRNA cancer vaccines¹

Delivering biomarkers for cell therapy response²

Research that empowers
effective biomarker discovery

Accelerating cancer biomarker
discovery and deployment^1,2

We can see
what others miss.